Bivalirudin as an anticoagulant reduces bleeding after percutaneous coronary intervention
(PCI), while its impact in elderly Chinese patients treated with PCI needs more evidence …

Although bivalirudin has been recently made available for purchase in China, large-scale
analyses on the safety profile of bivalirudin among Chinese patients is lacking. Thus, this …

Objective To assess the effectiveness and safety of bivalirudin compared with heparin
monotherapy in elderly patients undergoing percutaneous coronary intervention (PCI) …

Bivalirudin, as a direct thrombin inhibitor, is considered to be safer compared with other
anticoagulants, such as heparin; however, relevant data in China are unclear. The present …

Background: Bivalirudin reduces ischemic and hemorrhagic events in patients undergoing
primary percutaneous coronary intervention (PCI), but the safety and efficacy for such …

Objectives: This study aimed to analyze the impact of replacing heparin with bivalirudin in
octogenarians undergoing percutaneous coronary intervention (PCI) on postprocedure …

Purpose The aim of this study was to explore the safety and efficacy of bivalirudin in elderly
patients undergoing percutaneous coronary intervention (PCI). Methods An electronic …

Objectives We aimed to perform a gender‐based meta‐analysis of the outcome of
bivalirudin versus heparin in patients undergoing percutaneous coronary interventions …

Background Bivalirudin was widely used as an anticoagulant during coronary interventional
procedure in western countries. However, it was not available in China before this clinical …

Objective ST-segment elevation myocardial infarction (STEMI) is the most serious type of
acute coronary syndrome. This study aimed to investigate the efficacy and safety of …